Effects of Comorbidities and Choice of Treatment on Overall Survival: A Beaumont Experience

Files

Authors

Bilal M. Ali, Oakland University William Beaumont School of Medicine Student
Emma Herrman, Beaumont Health Resident
James Huang Huang, Beaumont Health
Mohammad Muhsin Chisti, Beaumont Health

Description

First line therapy for Acute Myeloid Leukemia (AML) is 7+3 regimen. It often cannot be used in elderly patients due to intensity. Venetoclax + hypomethylating agent (HMA) is approved for AML treatment in these patients. We investigate the efficacy of this treatment in a community setting where patients do not have the same resources available to them as a large academic center. Primary outcome was survival of patients greater than 60 years of age with a diagnosis of AML who received 7+3 therapy versus those who received venetoclax + HMA. Secondary outcomes included characteristics of those who received the two therapies.

Publication Date

5-2023

Disciplines

Hematology | Internal Medicine | Oncology | Pathology

Recommended Citation

Ali, Bilal, Herrman E, Huang J, Chisti MM. Effects of comorbidities and choice of treatment on overall survival: a Beaumont experience. Poster presented at: Oakland University William Beaumont School of Medicine Embark Capstone Colloquium; 2023 May; Rochester Hills, MI.

Comments

The Embark Capstone Colloquium at the Oakland University William Beaumont School of Medicine, Rochester Hills, MI, May, 2023.